BRD3731

Overview

BRD3731 is a selective GSK3β inhibitor, with IC 50 s of 15 nM and 215 nM for GSK3β and GSK3α, respectively. BRD3731 is potentail for the research of post-traumatic stress disorder (PTSD), psychiatric disorder, diabetes, and neurodegenerative disorders.

Application

Products | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Depression | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Obesity | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Stem Cell/Wnt | Products > Research Areas > Neurological Disease | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > GSK-3

Product Information

• Catalog No.: HY-124607B
• CAS No.: 2056262-07-6
• Molecular Formula: C24H31N3O
• Molecular Weight: 377.52
• Purity: 98.18%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 5 mg/mL (13.24 mM); Clear solution
• Availability: In-stock

Source

Original product source